journal
MENU ▼
Read by QxMD icon Read
search

Lancet Oncology

journal
https://www.readbyqxmd.com/read/29033198/copanlisib-in-heavily-pretreated-indolent-lymphoma
#1
Manjulika Das
No abstract text is available yet for this article.
October 12, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29033197/oncolytic-virus-therapy-in-advanced-melanoma
#2
Elizabeth Gourd
No abstract text is available yet for this article.
October 12, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29033196/first-line-obinutuzumab-for-follicular-lymphoma
#3
Holly Baker
No abstract text is available yet for this article.
October 12, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29031779/extended-adjuvant-therapy-the-role-of-subset-analyses
#4
Kathleen I Pritchard
No abstract text is available yet for this article.
October 11, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29031778/extended-adjuvant-aromatase-inhibition-after-sequential-endocrine-therapy-data-a-randomised-phase-3-trial
#5
Vivianne C G Tjan-Heijnen, Irene E G van Hellemond, Petronella G M Peer, Astrid C P Swinkels, Carolien H Smorenburg, Maurice J C van der Sangen, Judith R Kroep, Hiltje De Graaf, Aafke H Honkoop, Frans L G Erdkamp, Franchette W P J van den Berkmortel, Maaike de Boer, Wilfred K de Roos, Sabine C Linn, Alexander L T Imholz, Caroline M Seynaeve
BACKGROUND: The effect of extended adjuvant aromatase inhibition in hormone receptor-positive breast cancer after sequential endocrine therapy of tamoxifen followed by an aromatase inhibitor for a 5-year treatment period still needs clarification. To address this issue, we began the DATA study to assess different durations of anastrozole therapy after tamoxifen. METHODS: DATA was a prospective, randomised, open-label, multicentre, phase 3 study done in 79 hospitals in the Netherlands...
October 11, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29033099/custirsen-ogx-011-combined-with-cabazitaxel-and-prednisone-versus-cabazitaxel-and-prednisone-alone-in-patients-with-metastatic-castration-resistant-prostate-cancer-previously-treated-with-docetaxel-affinity-a-randomised-open-label-international-phase-3-trial
#6
Tomasz M Beer, Sebastien J Hotte, Fred Saad, Boris Alekseev, Vsevolod Matveev, Aude Fléchon, Gwenaelle Gravis, Florence Joly, Kim N Chi, Zafar Malik, Brent Blumenstein, Patricia S Stewart, Cindy A Jacobs, Karim Fizazi
BACKGROUND: Docetaxel and cabazitaxel improve overall survival compared with mitoxantrone in patients with metastatic castration-resistant prostate cancer. Custirsen (OGX011) is a second generation highly specific antisense oligonucleotide that inhibits the production of clusterin, an antiapoptotic protein that is upregulated in response to chemotherapy and that confers treatment resistance. We aimed to assess whether custirsen in combination with cabazitaxel and prednisone increases overall survival in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel...
October 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29033098/moving-toward-a-precision-medicine-approach-in-metastatic-castration-resistant-prostate-cancer
#7
Rahul Aggarwal
No abstract text is available yet for this article.
October 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28988912/maintenance-rituximab-in-mantle-cell-lymphoma
#8
Talha Khan Burki
No abstract text is available yet for this article.
October 5, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28988911/insulin-analog-linked-to-breast-cancer-risk
#9
Elizabeth Gourd
No abstract text is available yet for this article.
October 5, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28988646/pembrolizumab-in-advanced-soft-tissue-sarcoma-and-bone-sarcoma-sarc028-a-multicentre-two-cohort-single-arm-open-label-phase-2-trial
#10
Hussein A Tawbi, Melissa Burgess, Vanessa Bolejack, Brian A Van Tine, Scott M Schuetze, James Hu, Sandra D'Angelo, Steven Attia, Richard F Riedel, Dennis A Priebat, Sujana Movva, Lara E Davis, Scott H Okuno, Damon R Reed, John Crowley, Lisa H Butterfield, Ruth Salazar, Jaime Rodriguez-Canales, Alexander J Lazar, Ignacio I Wistuba, Laurence H Baker, Robert G Maki, Denise Reinke, Shreyaskumar Patel
BACKGROUND: Patients with advanced sarcomas have a poor prognosis and few treatment options that improve overall survival. Chemotherapy and targeted therapies offer short-lived disease control. We assessed pembrolizumab, an anti-PD-1 antibody, for safety and activity in patients with advanced soft-tissue sarcoma or bone sarcoma. METHODS: In this two-cohort, single-arm, open-label, phase 2 study, we enrolled patients with soft-tissue sarcoma or bone sarcoma from 12 academic centres in the USA that were members of the Sarcoma Alliance for Research through Collaboration (SARC)...
October 4, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28988645/pd-1-inhibition-in-bone-sarcoma-and-soft-tissue-sarcoma
#11
Olivier Mir, Charles Honoré, Julien Adam
No abstract text is available yet for this article.
October 4, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28986013/is-competition-bad-for-our-health-care-we-simply-don-t-know
#12
Kalipso Chalkidou
No abstract text is available yet for this article.
October 3, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28986012/effect-of-patient-choice-and-hospital-competition-on-service-configuration-and-technology-adoption-within-cancer-surgery-a-national-population-based-study
#13
Ajay Aggarwal, Daniel Lewis, Malcolm Mason, Arnie Purushotham, Richard Sullivan, Jan van der Meulen
BACKGROUND: There is a scarcity of evidence about the role of patient choice and hospital competition policies on surgical cancer services. Previous evidence has shown that patients are prepared to bypass their nearest cancer centre to receive surgery at more distant centres that better meet their needs. In this national, population-based study we investigated the effect of patient mobility and hospital competition on service configuration and technology adoption in the National Health Service (NHS) in England, using prostate cancer surgery as a model...
October 3, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28965744/adding-radiotherapy-to-chemotherapy-in-advanced-nsclc
#14
Vicki Brower
No abstract text is available yet for this article.
September 28, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28965743/inpatient-palliative-care-during-transplantation
#15
Ashray Gunjur
No abstract text is available yet for this article.
September 28, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28967486/new-option-for-cisplatin-ineligible-urothelial-cancer
#16
Robert Dreicer
No abstract text is available yet for this article.
September 26, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28967485/first-line-pembrolizumab-in-cisplatin-ineligible-patients-with-locally-advanced-and-unresectable-or-metastatic-urothelial-cancer-keynote-052-a-multicentre-single-arm-phase-2-study
#17
Arjun V Balar, Daniel Castellano, Peter H O'Donnell, Petros Grivas, Jacqueline Vuky, Thomas Powles, Elizabeth R Plimack, Noah M Hahn, Ronald de Wit, Lei Pang, Mary J Savage, Rodolfo F Perini, Stephen M Keefe, Dean Bajorin, Joaquim Bellmunt
BACKGROUND: More than half of all patients with advanced urothelial cancer cannot receive standard, first-line cisplatin-based chemotherapy because of renal dysfunction, poor performance status, or other comorbidities. We assessed the activity and safety of first-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer. METHODS: In this multicentre, single-arm, phase 2 study (KEYNOTE-052), cisplatin-ineligible patients with advanced urothelial cancer who had not been previously treated with systemic chemotherapy were recruited from 91 academic medical centres in 20 countries...
September 26, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28958504/rilotumumab-plus-epirubicin-cisplatin-and-capecitabine-as-first-line-therapy-in-advanced-met-positive-gastric-or-gastro-oesophageal-junction-cancer-rilomet-1-a-randomised-double-blind-placebo-controlled-phase-3-trial
#18
Daniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, André M Murad, Salah-Eddin Al-Batran, David H Ilson, Sergei Tjulandin, Evengy Gotovkin, Boguslawa Karaszewska, Igor Bondarenko, Mohamedtaki A Tejani, Anghel A Udrea, Mustapha Tehfe, Ferdinando De Vita, Cheryl Turkington, Rui Tang, Agnes Ang, Yilong Zhang, Tien Hoang, Roger Sidhu, David Cunningham
BACKGROUND: Rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the MET receptor, hepatocyte growth factor (HGF). We aimed to assess the efficacy, safety, and pharmacokinetics of rilotumumab combined with epirubicin, cisplatin, and capecitabine, and to assess potential biomarkers, in patients with advanced MET-positive gastric or gastro-oesophageal junction adenocarcinoma. METHODS: This multicentre, randomised, double-blind, placebo-controlled, phase 3 study was done at 152 centres in 27 countries...
September 25, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28958503/treatment-choice-in-egfr-mutant-non-small-cell-lung-cancer
#19
Wolfgang M Brueckl
No abstract text is available yet for this article.
September 25, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28958502/dacomitinib-versus-gefitinib-as-first-line-treatment-for-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-archer-1050-a-randomised-open-label-phase-3-trial
#20
Yi-Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, Rolf Linke, Rafael Rosell, Jesus Corral, Maria Rita Migliorino, Adam Pluzanski, Eric I Sbar, Tao Wang, Jane Liang White, Sashi Nadanaciva, Rickard Sandin, Tony S Mok
BACKGROUND: Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor. We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC). METHODS: In this international, multicentre, randomised, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centres and university hospitals in seven countries or special administrative regions...
September 25, 2017: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"